You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
DeCode Genetics researchers found patients' antibody titers increased in the two months following diagnosis, then stabilized.
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
The companies are aiming to develop Idylla-based CDx biomarker tests for a compound Amgen is developing to treat solid tumors.
The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.
Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.
At issue is the lack of reference samples for evaluating the performance of LDTs that may determine which patients are appropriate for specific cancer drugs.
The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL.